Skip to main content

Advertisement

SpringerLink
Log in

Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine

Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule

  • Original Papers
  • Published:
The European Journal of Health Economics, formerly: HEPAC Aims and scope Submit manuscript

Abstract

A new hexavalent combination vaccine, Infanrix-HEXA, including a recombinant hepatitis B vaccine in addition to the vaccines for diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type B, has recently become available in France. The objectives of this study were to: (1) estimate the break-even price of Infanrix-Hexa for the National Sickness Fund; (2) evaluate its potential impact on vaccine coverage for hepatitis B and the corresponding budget impact. The public price of Infanrix-HEXA associated with a break-even point would be € 53.77. Our analyses suggested that other estimates based on a societal perspective including opportunity and indirect costs remained close to this value. The annual additional reimbursed cost of protecting an infant against the risk of hepatitis B would be € 28.20 per child, or about € 21 million for an annual cohort of 760,000 births (total cost, € 35 million). The number of infants protected against hepatitis B could increase from 230,000 in the current situation to about 600,000.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Calendrier Vaccinal (2003) Avis du Conseil Supérieur d’Hygiène Publique de France. BEH 6:33–37

    Google Scholar 

  2. Bonanni P, Jilg W (2002) Influence of combined vaccines on infant immunisation coverage—recent data from Italy, Germany and Belgium. Viral Hepatitis 10:10–13

    Google Scholar 

  3. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA (1999) Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 354:2063–2068

    CAS  PubMed  Google Scholar 

  4. Conseil Supérieur d’Hygiène Publique de France (2002) Avis du Conseil Supérieur d’Hygiène Publique de France concernant la vaccination contre l’hépatite B virale. Séance du 4 mars. Bulletin Officiel Ministère Emploi Solidarité 13:377–378

    Google Scholar 

  5. Comité Technique des Vaccinations (1998) Avis du Comité Technique des Vaccinations et de la Section des Maladies Transmissibles du Conseil Supérieur d’Hygiène Publique de France concernant la vaccination contre l’hépatite B. Séance du 17 et du 23 juin. BEH 44–98

  6. Jacobson SH, Sewell EC (2002) Using Monte-Carlo simulation to determine combination vaccines price distribution for childhood disease. Health Care Manage Sci 5:135–45

    Article  Google Scholar 

  7. CDC (1999) Combination vaccines for childhood immunization. Morb Mortal Wkly Rep 48:1–15

    Google Scholar 

  8. Dietz VJ, Stevenson J, Zell ER, Cochi S, Hadler S, Eddins D (1994) Potential impact on vaccination coverage levels by administering vaccines simultaneously and reducing dropout rates. Arch Pediatr Adolesc Med 148:943–949

    CAS  PubMed  Google Scholar 

  9. Kuppermann M, Nease RF Jr, Ackerson LM, Black SB, Shinefield HR, Lieu TA (2000) Parents’ preferences for outcomes associated with childhood vaccinations. Pediat Infect Dis J 19:129–133

    Article  CAS  Google Scholar 

  10. Meyerhoff As, Weniger BG, Jacobs RJ (2001) Economic value to parents of reducing pain and emotional distress of childhood vaccine injections. Pediat Infect Dis J 20 [Suppl 11]:S57–62

  11. Dartigues JF (2002) Rapport Mission d’expertise sur la politique de vaccination contre l’hépatite B en France. Ministère de la Santé, Paris

  12. Bonanni P, Bergamini M (2002) Factors influencing vaccine uptake in Italy. Vaccine 20:S8–S12

    Article  Google Scholar 

  13. Swennen B, Van Damme P, Vellinga A, Coppieters Y, Depooter AM (2002) Analysis of factors influencing vaccine uptake: perspectives from Belgium. Vaccine 20:S5–S7

    Article  Google Scholar 

  14. Madlon-Kay D, Harper PG (1994) Too many shots? Parent, nurse and physician attitudes toward multiple simultaneous childhood vaccinations. Arch Fam Med 3:610–613

    Article  CAS  PubMed  Google Scholar 

  15. Lieu TA, Black SB, Ray GT (2000) The hidden costs of infant vaccination. Vaccine 19:33–41

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This study was supported by an unrestricted grant from GSK France.

Conflict of interest:

No comment.

Author information

Authors and Affiliations

  1. CEMKA, 43 Boulevard Maréchal Joffre , 92340, Bourg-la-Reine, France

    Francis Fagnani

  2. GSK, 100 Route de Versailles, 78163, Marly le Roi, France

    Camille Le Fur, Isabelle Durand & Michel Gibergy

Authors
  1. Francis Fagnani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Camille Le Fur
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabelle Durand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michel Gibergy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francis Fagnani.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fagnani, F., Le Fur, C., Durand, I. et al. Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. HEPAC 5, 143–149 (2004). https://doi.org/10.1007/s10198-003-0216-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-003-0216-z

Keywords

Search

Navigation